Stoke Therapeutics (STOK) Non Operating Income (2019 - 2026)

Stoke Therapeutics' Non Operating Income history runs 8 years deep, the most recent figure standing at $3.4 million for Q1 2026.

• In Q1 2026, Non Operating Income rose 17.07% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $24.3 million (up 54.7% YoY), while the FY2025 annual figure was $13.7 million, up 10.6% from the prior year.
• Non Operating Income was $3.4 million for Q1 2026 at Stoke Therapeutics, down from $13.6 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $13.6 million in Q4 2025 to a low of -$428000.0 in Q1 2024.
• Historically, Non Operating Income has averaged $2.9 million across 5 years, with a median of $2.6 million in 2023.
• Biggest YoY gain for Non Operating Income was 31214.63% in 2024; the steepest drop was 1119.05% in 2024.
• A 5-year view of Non Operating Income shows it stood at $3.2 million in 2022, then slumped by 98.7% to $41000.0 in 2023, then surged by 31214.63% to $12.8 million in 2024, then grew by 6.29% to $13.6 million in 2025, then plunged by 74.97% to $3.4 million in 2026.
• The last three Non Operating Income figures came in at $3.4 million (Q1 2026), $13.6 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.